Fluvoxamine: a $4 Antidepressant That Reduces COVID 19 Hospitalizations

submitted by New Youtube Tv on 11/29/21 1

Roger Seheult, MD of MedCram on how Fluvoxamine Maleate, an inexpensive SSRI medication FDA approved in 1994, was shown to reduce COVID 19 hospitalizations and deaths in a recent randomized placebo controlled trial published in the Lancet. Fluvoxamine (Luvox) was also compared to other medications such as ivermectin, metformin, and hydroxychloroquine in the trial. Update 134 (This video was recorded on November 1, 2021) TOPICS IN THIS VIDEO INCLUDE: 00:00 What is Fluvoxamine, how is it working to treat COVID-19 patients, and how did we get here? 00:42 JAMA Study from Nov. 2020: Fluvoxamine vs. Placebo and Clinical Deterioration in Patients with Symptomatic COVID-19 01:27 Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI): How do SSRIs work? 02:37 History of Fluvoxamine and known side effects 03:39 Why would researchers try an SSRI (Fluvoxamine) for COVID-19? Revisiting the role of Reactive Oxygen Species (ROS) and inflammatory factors 08:03 Breaking down the data from the smaller JAMA study on Fluvoxamine 10:36 Large-scale TOGETHER COVID-19 clinical trials: Is there a medication already in use that could be repurposed for SARS-CoV-2 treatment? 12:11 Medications studied in TOGETHER trial: Hydroxychloroquine, Lopinavir/Ritonavir, Metformin, Ivermectin, Doxazosin, Interferon Lambda, and Fluvoxamine 13:36 Ivermectin trial data 14:07 Fluvoxamine trial data: statistically significant at preventing hospitalization Roger Seheult, MD is the co-founder and lead professor at www.medcram.com He is Board Certified in Internal Medicine, Pulmonary Disease, Critical Care, and Sleep Medicine and an Associate Professor at the University of California, Riverside School of Medicine. LINKS / REFERENCES: Fluvoxamine in the treatment of anxiety disorders (PMC) | www.ncbi.nlm.nih.gov/pmc/articles/PMC2424117/ Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial (Lancet) | www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00448-4/fulltext Who We Are (Together Trial) | www.togethertrial.com/who-we-are The Sigma-1 Receptor in Cellular Stress Signaling (Frontiers in Neuroscience) | www.frontiersin.org/articles/10.3389/fnins.2019.00733/full All coronavirus updates are at MedCram.com (including more discussion on the COVID delta variant, fluvoxamine maleate, serotonin syndrome, fluvoxamine 100 mg, vaccine randomized trial and more). SUBSCRIBE TO THE MEDCRAM YOUTUBE CHANNEL: www.youtube.com/user/MEDCRAMvideos?sub_confirmation=1 Get notified of new videos by hitting the bell icon MEDCRAM WORKS WITH MEDICAL PROGRAMS AND HOSPITALS: MedCram offers group discounts for students and medical programs, hospitals, and other institutions. Contact us at customers@medcram.com if you are interested. MEDIA CONTACT: Media Contact: customers@medcram.com Media contact info: www.medcram.com/pages/media-contact Video Produced by Kyle Allred FOLLOW US ON SOCIAL MEDIA: www.facebook.com/MedCram twitter.com/MedCramVideos www.instagram.com/medcram DISCLAIMER: MedCram medical videos are for medical education and exam preparation, and NOT intended to replace recommendations from your doctor. #COVID19 #SARSCoV2 #Coronavirus

Leave a comment

Be the first to comment

Be the first to
collect this video
cover photo
Email
Message
×
Embed video on a website or blog
Width
px
Height
px
×
Join Huzzaz
Start collecting all your favorite videos
×
Log in
Join Huzzaz

facebook login
×
Retrieve username and password
Name
Enter your email address to retrieve your username and password
(Check your spam folder if you don't find it in your inbox)

×